Industry News

9 Dec

Monster Digital, Inc. Exhibits New Products at Hudson Group Show

SIMI VALLEY, CA–(Marketwired – Dec 9, 2016) – Monster Digital, Inc. ( NASDAQ : MSDI ) (“Monster Digital” or the “Company”), which develops, markets and distributes Monster Digital® branded products for use in high-performance consumer electronics, mobile products and computing applications, today announced exhibition of its new Virtual Reality...

Read more

8 Dec

EVERYTHING BUT THE HOUSE And Jerrick Partner For Bob Guccione Online Estate Sale

CINCINNATI, Dec. 8, 2016 /PRNewswire/ — EVERYTHING BUT THE HOUSE (EBTH), the world’s premier online marketplace for estate sales, and Jerrick (JMDA), a digital media and technology company focused on the development and marketing of branded digital content and e-commerce properties, announced the launch of The Guccione Collection, an online...

Read more

7 Dec

Ascent’s Lightweight Thin-Film Solar Selected for Further Evaluation by the Japan Aerospace Exploration Agency (JAXA) for Deep Space Missions

THORNTON, CO–(Marketwired – Dec 7, 2016) – Ascent Solar Technologies, Inc. (ASTI), a developer and manufacturer of state-of-the-art, lightweight and flexible thin-film photovoltaic (PV) solutions, announces that the Company was selected by the Japan Aerospace Exploration Agency (JAXA) as part of their next round of evaluations for providing solar...

Read more

7 Dec

CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis

NEWARK, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat indications with high unmet medical need, today announced the initiation of a new Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). PBC is an orphan...

Read more

6 Dec

Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting

SAN DIEGO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that results from its Phase 1 trial of Actimab-A were presented at the 58thAmerican Society of...

Read more

Page 1 of 20212345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address